Relative bioavailability in healthy volunteers of ciprofloxacin administered through a nasogastric tube with and without enteral feeding.

Antimicrobial Agents and Chemotherapy
J H YukR W Frost

Abstract

The bioavailability of ciprofloxacin after its administration through a nasogastric (NG) feeding tube was studied in six healthy volunteers. Each subject received, on separate occasions, an intact 750-mg ciprofloxacin tablet, a crushed tablet as a suspension through an NG tube, and a crushed tablet as a suspension through an NG tube while receiving enteral feeding. No statistically significant differences were observed in the area under the curve, maximum concentration in serum, and time to peak concentration among these three modes of administration. These findings suggest that ciprofloxacin is well absorbed after administration via an NG tube (compared with an orally administered intact tablet) even in the presence of enteral feeding.

References

Aug 2, 1986·Lancet·A M el-SharkawiM C Scott
Aug 2, 1986·Lancet·L W FlemingA C Scott
Apr 1, 1986·European Journal of Clinical Microbiology·T BerganS Johnsen
Jan 1, 1986·Antimicrobial Agents and Chemotherapy·T A TartaglioneT M Kerkering
Mar 1, 1985·Antimicrobial Agents and Chemotherapy·B LedergerberR Lüthy
Jun 1, 1985·European Journal of Clinical Microbiology·G HöffkenH Lode
Jun 1, 1987·Antimicrobial Agents and Chemotherapy·K I PlaisanceH C Standiford
Sep 1, 1986·Antimicrobial Agents and Chemotherapy·G L DrusanoJ Caldwell
Aug 1, 1984·European Journal of Clinical Microbiology·W WingenderP Schacht

❮ Previous
Next ❯

Citations

Apr 1, 1991·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·J S Wolfson, D C Hooper
Jul 1, 1994·International Journal of Antimicrobial Agents·C H Nightingale
Feb 6, 1999·American Journal of Surgery·J VincentH L Friedman
Mar 31, 1999·Journal of Pain and Symptom Management·P J Gilbar
Mar 1, 1990·Antimicrobial Agents and Chemotherapy·M H ChandlerJ A Korvick
Sep 1, 1994·Antimicrobial Agents and Chemotherapy·B A MuellerL Bowman
May 1, 2001·Clinical Pharmacokinetics·A AminimanizaniR Jelliffe
Aug 27, 2005·Clinical Pharmacokinetics·Olaf BurkhardtTobias Welte
Mar 13, 2002·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·W W Yew
Oct 20, 2005·Pharmacotherapy·Michael B KaysKevin M Sowinski
Jun 23, 2006·Journal of Clinical Pharmacy and Therapeutics·T KotakeH Morishita
May 1, 2001·Clinical Nutrition : Official Journal of the European Society of Parenteral and Enteral Nutrition·R Lourenço
Jul 21, 2010·Journal of Pharmaceutical and Biomedical Analysis·Zakelj SimonKristl Albin
Nov 7, 2016·JPEN. Journal of Parenteral and Enteral Nutrition·Joseph I BoullataUNKNOWN ASPEN Safe Practices for Enteral Nutrition Therapy Task Force, American Society for Parenteral and Enteral Nutrition
Jan 19, 2000·JPEN. Journal of Parenteral and Enteral Nutrition·D H WrightJ C Rotschafer
Feb 12, 2015·British Journal of Hospital Medicine·Gavin Tansley, Richard Hall
Apr 1, 1992·The Annals of Pharmacotherapy·R W Druckenbrod, D P Healy

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.